Sanofi (NASDAQ:SNY) announced on Thursday that it plans to repurchase €5 billion ($5.21 billion) worth of shares this year and may take a more active approach to acquisitions in the near term. The ...

Deutsche Bank has upgraded Sanofi (NASDAQ:SNY) to hold from sell, citing the company's Q4 earnings report. The investment ...

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

Fifth Third Bancorp reduced its stake in Sanofi (NASDAQ:SNY – Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Sanofi (NASDAQ:SNY – Get Free Report) was the target of unusually large options trading on Monday. Traders acquired 2,013 put options on the company. This is an increase of approximately 68% compared ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

Sanofi (NASDAQ:SNY – Free Report) – Investment analysts at Zacks Research raised their Q3 2025 EPS estimates for Sanofi in a report released on Wednesday, January 22nd. Zacks Research analyst K.

Sanofi Stock Performance NASDAQ:SNY opened at $52.48 on Friday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a twelve month low of ...

Janney Montgomery Scott LLC increased its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 5.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...